Copy number and targeted mutational analysis reveals novel somatic events in metastatic prostate tumors
about
The emerging role of histone lysine demethylases in prostate cancerCHD5, a brain-specific paralog of Mi2 chromatin remodeling enzymes, regulates expression of neuronal genesClonal origin and spread of metastatic prostate cancerRole of CHD5 in human cancers: 10 years laterChd5 requires PHD-mediated histone 3 binding for tumor suppressionThe mutational landscape of lethal castration-resistant prostate cancerAR intragenic deletions linked to androgen receptor splice variant expression and activity in models of prostate cancer progressionEstimation of copy number alterations from exome sequencing data.An evaluation of alternative methods for constructing phylogenies from whole genome sequence data: a case study with SalmonellaWhole-exome sequencing of circulating tumor cells provides a window into metastatic prostate cancer.Identification of FBXL4 as a Metastasis Associated Gene in Prostate Cancer.New strategies in prostate cancer: translating genomics into the clinicThe role of homeostatic regulation between tumor suppressor DAB2IP and oncogenic Skp2 in prostate cancer growth.Genomics screens for metastasis genesMultivalent recognition of histone tails by the PHD fingers of CHD5Integrative analysis of prostate cancer aggressiveness.Frequent disruption of chromodomain helicase DNA-binding protein 8 (CHD8) and functionally associated chromatin regulators in prostate cancerLow-grade prostate cancer diverges early from high grade and metastatic disease.Infant sex-specific placental cadmium and DNA methylation associations.Androgen receptor gene polymorphisms and alterations in prostate cancer: of humanized mice and men.Exome sequencing identifies a spectrum of mutation frequencies in advanced and lethal prostate cancers.Copy number alterations in prostate tumors and disease aggressivenessFOXA1: master of steroid receptor function in cancer.FOXA1 modulates EAF2 regulation of AR transcriptional activity, cell proliferation, and migration in prostate cancer cells.Studying clonal dynamics in response to cancer therapy using high-complexity barcoding.The tumour suppressor CHD5 forms a NuRD-type chromatin remodelling complex.The stromal genome heterogeneity between breast and prostate tumors revealed by a comparative transcriptomic analysis.A new branch on the tree: next-generation sequencing in the study of cancer evolution.Retinoic acid-induced CHD5 upregulation and neuronal differentiation of neuroblastoma.Transcriptome-wide detection of differentially expressed coding and non-coding transcripts and their clinical significance in prostate cancer.Flavokawain A induces deNEDDylation and Skp2 degradation leading to inhibition of tumorigenesis and cancer progression in the TRAMP transgenic mouse model.Novel oncogene-induced metastatic prostate cancer cell lines define human prostate cancer progression signatures.Cancer of the ampulla of Vater: analysis of the whole genome sequence exposes a potential therapeutic vulnerabilityMutations in critical domains confer the human mTOR gene strong tumorigenicity.Identification of novel CHD1-associated collaborative alterations of genomic structure and functional assessment of CHD1 in prostate cancer.Tumor-associated copy number changes in the circulation of patients with prostate cancer identified through whole-genome sequencing.Genomic profiling defines subtypes of prostate cancer with the potential for therapeutic stratificationSomatic alterations contributing to metastasis of a castration-resistant prostate cancerExperimental evidence of persistent androgen-receptor-dependency in castration-resistant prostate cancer.Biomarkers in prostate cancer epidemiology.
P2860
Q21245762-DEB71612-150B-4693-8494-DF467C240AB5Q24338318-4BF524B7-7074-4D1B-A5F3-425734DBDD55Q26752873-FE5B51B3-A6D9-42F8-88EA-3E4362048BB8Q27006929-D419F47E-AF23-4FD1-B37D-88E4B114B4C8Q28593132-F57A660D-18EA-40C1-9ACF-B93D7DDE1847Q29614634-C8CB1983-B515-4CAB-969A-17F326B83F01Q30513836-4FAAD807-F220-45BE-83C1-97A9E1DB925AQ30584272-3FAAC5AC-3579-4EE8-AE5D-D802327121A7Q30863381-A35AD4F1-453E-4CCB-9CF9-9231F381423CQ33667666-DBE75D9A-7CCC-4245-8905-2969739D7160Q33894922-0B04C20E-D10A-4029-A5C4-57EC28055213Q34007943-CF2C1593-F4EB-46E5-B683-36A818BF0E29Q34227747-0F2E0555-8257-4F6B-91C3-4D70A19363C3Q34298860-BC1AC94F-F784-4AA9-A632-F368A84F7FA6Q34352597-AD40D3D8-3188-4D60-857B-E7C80EDA3E7CQ34787486-B0C70ABC-0FD1-4A95-9D74-660E458F6157Q35022469-46ED1CA6-5F50-4C79-99AE-5495CE751519Q35180364-B9B890B1-A307-40DD-82FD-609215751EBAQ35269248-147E34E5-3CAB-41CE-8B97-C359F6C720FAQ35281575-8A21881B-6436-4D01-AB85-D895C7A70EE5Q35345680-0A219A63-0734-46FC-858E-209D074AF17FQ35531720-4AAD290D-21E4-4520-8F53-D50FDB340F5AQ35532767-965E134D-5A33-4910-982D-60C12453BC5DQ35582347-555D3DDF-B2C3-41FC-A18E-D56A9A99D4CDQ35596310-98A9D740-2D6A-4AD6-AC64-876843581514Q35806478-7F512CB7-54CA-4BF1-87DF-917C6D175BD3Q35832205-7E0C9697-525B-4E59-9F86-2FC862669978Q35857148-A190BE98-9E8D-499C-BA22-D828DDB512EAQ35923727-7C9DFDE4-E116-4CE6-BBBE-AB248B6DB53AQ36200124-3B3E63E7-E90A-4594-B80E-96ED754040E7Q36561595-06B8D4C8-EE68-4096-9A56-2AE87E516B2FQ36580194-D8B15CE2-3A8D-438D-80EF-BF52212FBC28Q36632860-5C9319CD-5100-4183-A027-A28E66DA62DEQ36647365-4E4DE334-1EF4-4215-B3D0-E2D11573799FQ36886070-ADA57AF2-F70F-4B5B-B26A-B3812039ABF2Q36998629-041CACE6-A321-41AE-BC00-E7574D8FB2D0Q37067529-F28CC502-CEF3-479D-811F-C64A883D5249Q37100131-9760B178-378A-437A-9574-A1BD5F5EF871Q37139070-DD8819B2-278F-4872-8088-479AD7391B4CQ37148139-275E01C5-6F0C-4B34-BF71-885E903B440E
P2860
Copy number and targeted mutational analysis reveals novel somatic events in metastatic prostate tumors
description
2010 nî lūn-bûn
@nan
2010 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Copy number and targeted mutat ...... in metastatic prostate tumors
@ast
Copy number and targeted mutat ...... in metastatic prostate tumors
@en
Copy number and targeted mutat ...... in metastatic prostate tumors
@nl
type
label
Copy number and targeted mutat ...... in metastatic prostate tumors
@ast
Copy number and targeted mutat ...... in metastatic prostate tumors
@en
Copy number and targeted mutat ...... in metastatic prostate tumors
@nl
prefLabel
Copy number and targeted mutat ...... in metastatic prostate tumors
@ast
Copy number and targeted mutat ...... in metastatic prostate tumors
@en
Copy number and targeted mutat ...... in metastatic prostate tumors
@nl
P2093
P2860
P356
P1433
P1476
Copy number and targeted mutat ...... in metastatic prostate tumors
@en
P2093
Angela Baker
Arul Chinnaiyan
Christiane M Robbins
David B Agus
David W Craig
Edward Suh
James Long
James Lowey
John D Carpten
John V Pearson
P2860
P356
10.1101/GR.107961.110
P577
2010-12-08T00:00:00Z